Do Antibiotic Combinations Prevent the Emergence of Resistant Organisms?
- 1 September 1988
- journal article
- review article
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 9 (9) , 417-419
- https://doi.org/10.1086/645901
Abstract
Antibiotic combinations are often used in the therapy of infectious diseases to broaden the antibacterial spectrum and to enhance antimicrobial activity. Another potential reason for combination therapy is to reduce or prevent the emergence of resistant organisms during therapy. Antituberculous chemotherapy provides a classic example in which drug combinations have successfully prevented the emergence of drug-resistant organisms and improved clinical outcome. The purpose of this brief report is to review the success of combination therapy in preventing resistance in more common bacterial infections.The emergence of resistance during single-drug therapy is a well-documented clinical phenomenon, especially with the broad-spectrum ß-lactams against gram-negative bacilli. As with Mycobacterium tuberculosis, the resistant organisms are generally thought to be naturally occurring mutants selected by drug exposure. Because mutation frequencies appear to vary from 10-6 to 10-8, it is not surprising that emergence of resistant organisms observed clinically occurs primarily at sites of high organism density, such as the respiratory and urinary tracts.Keywords
This publication has 32 references indexed in Scilit:
- CROSS-RESISTANCE AND IMIPENEMThe Lancet, 1986
- Emergence of Resistance to -Lactams, Aminoglycosides, and Quinolones During Combination Therapy for Infection Due to Serratia marcescensThe Journal of Infectious Diseases, 1986
- Hydrolytic Model for Cefotaxime and Ceftriaxone Resistance in -Lactamase-Derepressed Enterobacter cloacaeThe Journal of Infectious Diseases, 1986
- Amikacin + Ceftazidime Therapy of Experimental Right-Sided Pseudomonas aeruginosa Endocarditis in RabbitsChemotherapy, 1985
- Mutational resistance to 4-quinolone antibacterial agentsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1984
- Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-PlaceboThe Journal of Infectious Diseases, 1983
- Selection of Aminoglycoside-Resistant Variants of Pseudomonas aeruginosa in an in Vivo ModelThe Journal of Infectious Diseases, 1982
- Selection of Small-Colony Variants of Enterobacteriaceae by in Vitro Exposure to Aminoglycosides: Pathogenicity for Experimental AnimalsThe Journal of Infectious Diseases, 1979
- The mechanisms of resistance to aminoglycosides in the genus PseudomonasJournal of Antimicrobial Chemotherapy, 1978
- Therapy of Neutropenic Rats Infected with Pseudomonas aeruginosaThe Journal of Infectious Diseases, 1976